ATE468855T1 - Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie - Google Patents

Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie

Info

Publication number
ATE468855T1
ATE468855T1 AT03772561T AT03772561T ATE468855T1 AT E468855 T1 ATE468855 T1 AT E468855T1 AT 03772561 T AT03772561 T AT 03772561T AT 03772561 T AT03772561 T AT 03772561T AT E468855 T1 ATE468855 T1 AT E468855T1
Authority
AT
Austria
Prior art keywords
combination
nitrogen mustard
treatment
imatinib
lymphatic leukemia
Prior art date
Application number
AT03772561T
Other languages
German (de)
English (en)
Inventor
Lawrence Panasci
Raquel Aloyz
Original Assignee
Jewish General Hospital
Panasci Lawrence Carl
Aloyz Raquel Silvia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jewish General Hospital, Panasci Lawrence Carl, Aloyz Raquel Silvia filed Critical Jewish General Hospital
Application granted granted Critical
Publication of ATE468855T1 publication Critical patent/ATE468855T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AT03772561T 2002-11-12 2003-11-10 Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie ATE468855T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42548102P 2002-11-12 2002-11-12
PCT/IB2003/005454 WO2004043466A1 (en) 2002-11-12 2003-11-10 Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia

Publications (1)

Publication Number Publication Date
ATE468855T1 true ATE468855T1 (de) 2010-06-15

Family

ID=32312996

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03772561T ATE468855T1 (de) 2002-11-12 2003-11-10 Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie

Country Status (11)

Country Link
US (2) US20060122186A1 (enExample)
EP (1) EP1578426B1 (enExample)
JP (1) JP4854198B2 (enExample)
CN (1) CN100475212C (enExample)
AT (1) ATE468855T1 (enExample)
AU (1) AU2003280191A1 (enExample)
BR (1) BR0316126A (enExample)
CA (1) CA2504665C (enExample)
DE (1) DE60332762D1 (enExample)
ES (1) ES2348140T3 (enExample)
WO (1) WO2004043466A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
WO2009082662A1 (en) 2007-12-21 2009-07-02 Novartis Ag Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia
WO2009120493A2 (en) * 2008-03-27 2009-10-01 Yaupon Therapeutics, Inc Stabilized compositions of alkylating agents and methods of using same
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN105997981A (zh) * 2016-06-13 2016-10-12 崔坤峰 苯丁酸氮芥的药物组合物及其抗抑郁的医药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506257A (en) * 1992-03-26 1996-04-09 University Of British Columbia Aminocyclohexylamides for antiarrhythmic and anaesthetic uses
CN1088777A (zh) * 1992-12-18 1994-07-06 丛繁滋 用于癌病灶直接给药的化疗药物制剂的制备方法
AU2003232115A1 (en) * 2002-05-13 2003-11-11 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of graft failure

Also Published As

Publication number Publication date
JP4854198B2 (ja) 2012-01-18
CA2504665A1 (en) 2004-05-27
JP2006508118A (ja) 2006-03-09
ES2348140T3 (es) 2010-11-30
US20060122186A1 (en) 2006-06-08
WO2004043466A1 (en) 2004-05-27
BR0316126A (pt) 2005-09-27
CA2504665C (en) 2012-12-18
AU2003280191A1 (en) 2004-06-03
CN100475212C (zh) 2009-04-08
CN1711090A (zh) 2005-12-21
EP1578426B1 (en) 2010-05-26
US20090312290A1 (en) 2009-12-17
US8492383B2 (en) 2013-07-23
EP1578426A1 (en) 2005-09-28
DE60332762D1 (de) 2010-07-08

Similar Documents

Publication Publication Date Title
DE60118430D1 (de) Behandlung gastrointestinaler stroma-tumoren
MY128664A (en) Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
ATE468855T1 (de) Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie
DE60308337D1 (de) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide zur behandlung von ang-ii vermittelt krankheiten
DK1471916T3 (da) Behandling af rheumatoid arthritis under anvendelse af imatinib
DE602004022540D1 (de) Verwendung von tyrosin-kinase-hemmern zur behandlung von diabetes
AU2003216621A8 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
DE60305460D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
BR0312242A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida para o tratamento da fibrose pulmonar
WO2004026930A3 (en) The method for reducing inflammation using sti-571 or its salt
WO2004103374A3 (en) Imatinib combinations for head and neck cancers
DE602005025514D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms
HK1097535A (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties